Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HBPCF Helix Biopharma	$0.60	$0.60	$0.59 ▼ $0.60	$31.81M	-0.13	1 shs	N/A
NWPHF Newron Pharmaceuticals	$9.36	$9.36	$9.10 ▼ $12.00	$167.08M	0.53	600 shs	N/A
PRTK Paratek Pharmaceuticals	$2.23	$2.22	$1.29 ▼ $3.65	$127.82M	1.7	724,253 shs	N/A
TYME Tyme Technologies	$0.31	$0.30	$0.22 ▼ $1.14	$53.51M	0.93	1.01 million shs	2.68 million shs
VTVT vTv Therapeutics	$16.46 +2.8%	$17.60	$12.12 ▼ $26.99	$52.51M	0.58	22,914 shs	6,550 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HBPCF Helix Biopharma	0.00%	0.00%	0.00%	+31.90%	+335.73%
NWPHF Newron Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-22.00%
PRTK Paratek Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
TYME Tyme Technologies	0.00%	0.00%	0.00%	0.00%	0.00%
VTVT vTv Therapeutics	+6.06%	+9.13%	-3.96%	-13.60%	-11.55%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HBPCF Helix Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NWPHF Newron Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PRTK Paratek Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TYME Tyme Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VTVT vTv Therapeutics	1.9833 of 5 stars	3.5	4.0	0.0	0.0	0.0	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HBPCF Helix Biopharma	0.00	N/A	N/A	N/A
NWPHF Newron Pharmaceuticals	0.00	N/A	N/A	N/A
PRTK Paratek Pharmaceuticals	0.00	N/A	N/A	N/A
TYME Tyme Technologies	0.00	N/A	N/A	N/A
VTVT vTv Therapeutics	3.00	Buy	$35.50	113.21% Upside

Current Analyst Ratings Breakdown

Latest VTVT, TYME, PRTK, HBPCF, and NWPHF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
4/9/2025	VTVT vTv Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$36.00

(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HBPCF Helix Biopharma	N/A	N/A	N/A	N/A	N/A	N/A
NWPHF Newron Pharmaceuticals	$6.82M	24.50	N/A	N/A	$0.21 per share	44.57
PRTK Paratek Pharmaceuticals	$160.27M	0.80	N/A	N/A	($3.08) per share	-0.72
TYME Tyme Technologies	N/A	N/A	N/A	N/A	$0.47 per share	N/A
VTVT vTv Therapeutics	$1.02M	52.07	N/A	N/A	$4.48 per share	3.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HBPCF Helix Biopharma	-$6.82M	-$0.14	N/A	∞	N/A	N/A	N/A	-747.46%	N/A
NWPHF Newron Pharmaceuticals	-$17.63M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
PRTK Paratek Pharmaceuticals	-$63.57M	-$1.10	N/A	∞	N/A	-35.44%	N/A	-40.05%	N/A
TYME Tyme Technologies	-$23.63M	-$0.14	N/A	∞	N/A	N/A	-28.30%	-26.21%	N/A
VTVT vTv Therapeutics	-$18.46M	-$3.01	N/A	∞	N/A	N/A	-121.46%	-46.75%	8/6/2025 (Estimated)

Latest VTVT, TYME, PRTK, HBPCF, and NWPHF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
6/16/2025	Q3 2025	HBPCF Helix Biopharma	N/A	-$0.02	N/A	-$0.02	N/A	N/A
5/15/2025	Q1 2025	VTVT vTv Therapeutics	-$0.73	-$0.77	-$0.04	-$0.77	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HBPCF Helix Biopharma	N/A	N/A	N/A	N/A	N/A
NWPHF Newron Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PRTK Paratek Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TYME Tyme Technologies	N/A	N/A	N/A	N/A	N/A
VTVT vTv Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HBPCF Helix Biopharma	N/A	0.42	0.42
NWPHF Newron Pharmaceuticals	N/A	N/A	N/A
PRTK Paratek Pharmaceuticals	N/A	0.52	0.46
TYME Tyme Technologies	N/A	14.06	14.06
VTVT vTv Therapeutics	N/A	7.39	7.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HBPCF Helix Biopharma	N/A
NWPHF Newron Pharmaceuticals	N/A
PRTK Paratek Pharmaceuticals	53.60%
TYME Tyme Technologies	16.69%
VTVT vTv Therapeutics	17.51%

Insider Ownership

Company	Insider Ownership
HBPCF Helix Biopharma	7.60%
NWPHF Newron Pharmaceuticals	N/A
PRTK Paratek Pharmaceuticals	8.00%
TYME Tyme Technologies	16.90%
VTVT vTv Therapeutics	1.34%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HBPCF Helix Biopharma	9	53.02 million	48.99 million	Not Optionable
NWPHF Newron Pharmaceuticals	22	17.85 million	N/A	Not Optionable
PRTK Paratek Pharmaceuticals	268	57.32 million	52.74 million	Optionable
TYME Tyme Technologies	17	172.21 million	143.10 million	Optionable
VTVT vTv Therapeutics	9	3.19 million	3.15 million	Not Optionable

VTVT, TYME, PRTK, HBPCF, and NWPHF Headlines

Recent News About These Companies

vTv Therapeutics Inc (VTVT) Share Chat - Investing.com UK

June 29, 2025 | uk.investing.com

VTVT - vTv Therapeutics Inc Class A Chart - Morningstar

June 27, 2025 | morningstar.comM

vTv Therapeutics (NASDAQ:VTVT) Stock Passes Below 50 Day Moving Average - Time to Sell?

June 27, 2025 | marketbeat.com

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series

June 11, 2025 | globenewswire.com

vTv resumes Phase III oral T1D drug study

May 21, 2025 | thepharmaletter.comT

vTv Therapeutics Appoints Michael Tung, M.D., MBA as Executive Vice President and Chief Financial Officer

May 19, 2025 | quiverquant.comQ

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

May 19, 2025 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: vTv Therapeutics (VTVT) and Precision BioSciences (DTIL)

May 17, 2025 | theglobeandmail.com

vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update

May 15, 2025 | globenewswire.com

vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes

May 15, 2025 | globenewswire.com

vTv Therapeutics Appoints Barry Brown as Interim CFO

April 11, 2025 | tipranks.com

vTv Therapeutics initiated with a Buy at H.C. Wainwright

April 9, 2025 | markets.businessinsider.com

HC Wainwright & Co. Initiates Coverage of vTv Therapeutics (VTVT) with Buy Recommendation

April 9, 2025 | msn.com

vTv Therapeutics cleared to resume clinical trial of diabetes therapy

March 26, 2025 | ncbiotech.orgN

vTv Therapeutics reports Q4 EPS (55c) vs ($1.67) last year

March 21, 2025 | markets.businessinsider.com

vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

March 20, 2025 | globenewswire.com

vTv Therapeutics Inc.: vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

March 18, 2025 | finanznachrichten.de

Alliance Global says clinical hold lift ‘de-risking’ event for vTv Therapeutics

March 18, 2025 | markets.businessinsider.com

vTv Therapeutics says FDA has lifted clinical hold on cadisegliatin program

March 17, 2025 | markets.businessinsider.com

vTv Therapeutics stock surges on FDA update

March 17, 2025 | au.investing.com

Vtv Therapeutics Shares Halted as FDA Clinical Hold on Diabetes Treatment Lifted

March 17, 2025 | marketwatch.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTVT, TYME, PRTK, HBPCF, and NWPHF Company Descriptions

Helix Biopharma OTCMKTS:HBPCF

$0.60 0.00 (0.00%)

As of 07/8/2025

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.

Newron Pharmaceuticals OTCMKTS:NWPHF

$9.36 0.00 (0.00%)

As of 07/8/2025

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.

Paratek Pharmaceuticals NASDAQ:PRTK

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.

Tyme Technologies NASDAQ:TYME

Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.

vTv Therapeutics NASDAQ:VTVT

$16.46 +0.45 (+2.81%)

Closing price 04:00 PM Eastern

Extended Trading

$16.70 +0.24 (+1.49%)

As of 04:40 PM Eastern

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time